Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis

Clinical Rheumatology

Volumn 35, Issue 7, 2016, Pages 1795-1803

  Ungprasert, Patompong ^a,b   Thongprayoon, Charat ^a   Davis, John M ^a  

^a MAYO CLINIC   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Biologic agents; Meta analysis; Psoriatic arthritis; Systematic review; TNF inhibitors

Indexed keywords

ABATACEPT; APREMILAST; SECUKINUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; ADALIMUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR;

ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC;

ABATACEPT; ADALIMUMAB; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL FACTORS; ETANERCEPT; HUMANS; INFLIXIMAB; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84957549751     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-016-3204-2     Document Type: Article

References (35)

1. Boehncke WH, Schon MP (2015) Psoriasis. Lancet 386:983–994
2. Huynh D, Kavanaugh A (2015) Psoriatic arthritis: current therapy and future approaches. Rheumatology (Oxford) 54:20–28
3. Anandarajah AP, Ritchlin CT (2009) The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheumatol 5:634–641
4. Gladman DD, Antoni C, Mease P et al (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl 2):ii14–ii17
5. Walsh JA, McFadden ML, Morgan MD et al (2014) Work productivity loss and fatigue in psoriatic arthritis. J Rheumatol 41:1670–1674
6. Ungprasert P, Sanguankeo A, Upala S, Suksaranjit P (2014) Psoriasis and risk of venous thromboembolism: a systematic review and meta-analysis. QJM 107:793–797
7. Benson MM, Frishman WH (2015) The heartbreak of psoriasis: a review of cardiovascular risk in patients with psoriasis. Cardiol Rev 23:312–316
8. Kingsley GH, Kowalczyk A, Taylor H et al (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 51:1368–1377
9. Willkens RF, Williams HJ, Ward JR et al (1984) Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 27:376–381
10. Soriano ER, McHugh NJ (2006) Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 33:1422–1430
11. Antoni C, Krueger GG, de Vlam K et al (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64:1150–1157
12. Mease PJ, Gladman DD, Ritchlin CT et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:3279–3289
13. Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385–390
14. Kavanaugh A, McInnes I, Mease P et al (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976–986
15. Mease PJ, Fleischmann R, Deodhar AA et al (2014) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73:48–55
16. Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12
17. Felson DT, Anderson JJ, Boers M et al (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 36:729–740
18. Hedges LV, Vevea JL (1998) Fixed- and random-effects models in meta-analysis. Psychol Methods 3:486–504
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
20. Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50:683–691
21. Song F, Altman DG, Glenny AM, Deeks JJ (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326:472
22. Gottlieb A, Menter A, Mendelsohn A et al (2009) Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373:633–640
23. Schett G, Wollenhaupt J, Papp K et al (2012) Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 64:3156–3167
24. Mease P, Genovese MC, Gladstein G et al (2011) Abatacept in the treatment of patients with psoriatic arthritis. Results of six-month, multicenter, randomized, double-blind, placebo–controlled, phase II trial. Arthritis Rheum 63:939–948
25. Ritchlin C, Rahman P, Kavanaugh A et al (2014) Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73:990–999
26. Kavanaugh A, Mease PJ, Gomez-Reino JJ et al (2014) Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73:1020–1026
27. Mease PJ, McInnes IB, Kirkham B et al (2015) Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 373:1329–1339
28. McInnes IB, Mease PJ, Kirkham B et al (2015) Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 386:1137–1146
29. Glintborg B, Østergaard M, Dreyer L et al (2011) Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 63:382–390
30. Antoni CE, Kavanaugh A, Kirkham B et al (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52:1227–1236
31. Genovese MC, Mease PJ, Thomson GT et al (2007) Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 34:1040–1050
32. Mease PJ, Kivitz AJ, Burch FX et al (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50:2264–2272
33. Lemos LL, de Oliveira CJ, Almeida AM et al (2014) Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int 34:1345–1360
34. Yildiz A, Vieta E, Correll CU, Nikodem M, Baldessarini RJ (2014) Critical issues on the use of network meta-analysis in psychiatry. Harv Rev Psychiatry 22:367–372
35. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP (2014) Evaluating the quality of evidence from a network meta-analysis. PLoS One 9:e99682